(Q36723801)

15 August 2017

1 reference

title

Role of integrase inhibitors in the treatment of HIV disease (English)

1 reference

15 August 2017

Lucia Palmisano

1

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

67-75

1 reference

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

The survival benefits of AIDS treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

The global status of resistance to antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Comparative architecture of transposase and integrase complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

New insight on the role of extrachromosomal retroviral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Structure and function of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Reversal of Integration and DNA Splicing Mediated by Integrase of Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Inhibitors of human immunodeficiency virus integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

A rapid in vitro assay for HIV DNA integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

A novel assay for the DNA strand-transfer reaction of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Integrase inhibitors to treat HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

Chemokine antagonists as therapeutics: focus on HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.1.67

21 January 2018

Identifiers

DOI

10.1586/14787210.5.1.67

1 reference

15 August 2017

1 reference